ArticleScientific reports2015
Screening of aptamers specific to colorectal cancer cells and stem cells by utilizing On-chip Cell-SELEX.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Aptamers used for biosensors and targeted therapy.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Pooled it
- SELEX-Based Aptamer Technologies for Toxin Analysis: Screening, Optimization, and Computational Assisted Design.Toxins · 2026Review
- A label-free DNAzyme-based colorimetric sensor for the detection of Leptospira interrogans.World journal of microbiology & biotechnology · 2024Article
- A comparative study of aptamer isolation by conventional and microfluidic strategies.The Analyst · 2023Article
- In vitro selection of DNA aptamers against human osteosarcoma.Investigational new drugs · 2022Article
- Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications Thereof.Pharmaceutics · 2021Review
- Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?Molecular therapy. Nucleic acids · 2020Review
- Discovery and characterization of a novel peptide inhibitor against influenza neuraminidase.RSC medicinal chemistry · 2020Article
- Advancements in Cancer Stem Cell Isolation and Characterization.Stem cell reviews and reports · 2019Review
- Microfluidic platforms for rapid screening of cancer affinity reagents by using tissue samples.Biomicrofluidics · 2018Article
- Aptamers: novelty tools for cancer biology.Oncotarget · 2018Review
- 3D modeling of cancer stem cell niche.Oncotarget · 2018Review
- Novel RNA aptamers targeting gastrointestinal cancer biomarkers CEA, CA50 and CA72-4 with superior affinity and specificity.PloS one · 2018Article
- Development of Cell-Specific Aptamers: Recent Advances and Insight into the Selection Procedures.Molecules (Basel, Switzerland) · 2017Review
- Aptamer Cell-Based Selection: Overview and Advances.Biomedicines · 2017Review
- Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects.Biomedicines · 2017Review
- Automated selection of aptamers against cholangiocarcinoma cells on an integrated microfluidic platform.Biomicrofluidics · 2017Article
- A Microfluidic Chip for Detecting Cholangiocarcinoma Cells in Human Bile.Scientific reports · 2017Article
- An integrated microfluidic system for the isolation and detection of ovarian circulating tumor cells using cell selection and enrichment methods.Biomicrofluidics · 2017Article
- Single cell biology beyond the era of antibodies: relevance, challenges, and promises in biomedical research.Cellular and molecular life sciences : CMLS · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the most frequently diagnosed cancer around the world, causing about 700,000 deaths every year. It is clear now that a small fraction of CRC, named colorectal cancer stem cells (CSCs) exhibiting self-renewal and extensive proliferative activities, are hard to be eradicated. Unfortunately, highly specific biomarkers for colorectal CSC (CR-CSCs) are lacking that prohibits the development of effective therapeutic strategies. This study designed and manufactured a novel microfluidic system capable of performing a fully automated cell-based, systematic evolution of ligands by exponential enrichment (SELEX) process. Eight CR-CSC/CRC-specific aptamers were successfully selected using the microfluidic chip. Three of the aptamers showed high affinities towards their respective target cells with a dissociation constant of 27.4, 28.5 and 12.3 nM, which are comparable to that of antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.